Insights

Innovative Pain Products Scilex Pharmaceuticals has a strong portfolio of non-opioid pain management products, including ZTlido, GLOPERBA, and ELYXYB, which are FDA-approved and recently launched. These products offer opportunities to expand sales through pain clinics, hospitals, and primary care providers seeking safer pain relief options.

Pipeline Expansion With promising pipeline candidates like SEMDEXA and SP-103, Scilex is poised to introduce next-generation pain therapies. Business opportunities exist in early-stage clinical markets and specialty pain centers looking to adopt innovative treatment options before competitors.

Strategic Partnerships Recent collaborations, including partnerships with Biconomy and investments in AI and cryptocurrency companies, suggest a readiness to explore new technologies and markets. These initiatives present cross-selling opportunities with digital health solutions and innovative financing models.

Market Presence Having launched ZTlido in 2018 and expanding with GLOPERBA and ELYXYB, Scilex demonstrates a growing market footprint. Building relationships with distributors, pharmacy chains, and healthcare providers can accelerate product adoption and drive revenue growth.

Financial Outlook With revenue estimated between $25 million and $50 million, Scilex is a mid-stage company actively increasing its product offerings. Engaging with this expanding firm offers chances to collaborate on sales channels, co-marketing efforts, and educational initiatives to capitalize on their growth trajectory.

Scilex Holding Company Tech Stack

Scilex Holding Company uses 8 technology products and services including Site Kit, BitPay, Cloudflare, and more. Explore Scilex Holding Company's tech stack below.

  • Site Kit
    Analytics
  • BitPay
    Blockchain
  • Cloudflare
    Content Management System
  • Element UI
    Javascript Frameworks
  • jQuery
    Javascript Libraries
  • DocuSign
    Miscellaneous
  • HTTP/3
    Web & Portal Technology
  • Nginx
    Web Servers

Media & News

Scilex Holding Company's Email Address Formats

Scilex Holding Company uses at least 2 format(s):
Scilex Holding Company Email FormatsExamplePercentage
FLast@scilexpharma.comJDoe@scilexpharma.com
94%
Last@scilexpharma.comDoe@scilexpharma.com
5%
FL@scilexpharma.comJD@scilexpharma.com
1%
FLast@scilexholding.comJDoe@scilexholding.com
100%

Frequently Asked Questions

Where is Scilex Holding Company's headquarters located?

Minus sign iconPlus sign icon
Scilex Holding Company's main headquarters is located at 960 San Antonio Road 100 Palo Alto, California 94303 United States. The company has employees across 3 continents, including North AmericaAsiaEurope.

What is Scilex Holding Company's phone number?

Minus sign iconPlus sign icon
You can contact Scilex Holding Company's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Scilex Holding Company's official website and social media links?

Minus sign iconPlus sign icon
Scilex Holding Company's official website is scilexholding.com and has social profiles on LinkedInCrunchbase.

What is Scilex Holding Company's NAICS code?

Minus sign iconPlus sign icon
Scilex Holding Company's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Scilex Holding Company have currently?

Minus sign iconPlus sign icon
As of February 2026, Scilex Holding Company has approximately 67 employees across 3 continents, including North AmericaAsiaEurope. Key team members include Head Market Access: B. L.Interim General Counsel And Chief Compliance Officer: S. L.Vice President, Research And Development: K. V.. Explore Scilex Holding Company's employee directory with LeadIQ.

What industry does Scilex Holding Company belong to?

Minus sign iconPlus sign icon
Scilex Holding Company operates in the Pharmaceutical Manufacturing industry.

What technology does Scilex Holding Company use?

Minus sign iconPlus sign icon
Scilex Holding Company's tech stack includes Site KitBitPayCloudflareElement UIjQueryDocuSignHTTP/3Nginx.

What is Scilex Holding Company's email format?

Minus sign iconPlus sign icon
Scilex Holding Company's email format typically follows the pattern of FLast@scilexpharma.com. Find more Scilex Holding Company email formats with LeadIQ.

When was Scilex Holding Company founded?

Minus sign iconPlus sign icon
Scilex Holding Company was founded in 2019.

Scilex Holding Company

Pharmaceutical ManufacturingCalifornia, United States51-200 Employees

SCILEX HOLDING COMPANY (Nasdaq: SCLX, “Scilex”), is dedicated to the development and commercialization of non-opioid pain management products. We are uncompromising in our focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life.

The company’s lead product ZTlido® (lidocaine topical system) 1.8%, is a marketed prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with Post-Herpetic Neuralgia (PHN), which is a form of post-shingles nerve pain. ZTlido® possesses novel delivery and adhesion technology designed to address many of the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief. Click here for ZTLido’s Important Safety Information and US Prescribing Information.

We have acquired two FDA approved non-opioid pain products, GLOPERBA® and ELYXYB®. GLOPERBA® is indicated for the prophylaxis of gout flares in adults. Elyxyb is indicated for the acute treatment of migraine with or without aura in adults. We launched ELYXYB® in the U.S. in 2023 and launched and began commercializing GLOPERBA® in 2024.

SCILEX is committed to harnessing the power of revolutionary delivery technologies designed to safely and effectively provide therapies to patients who need them the most.

Our pipeline product candidates are

(i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA™”), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain;
(ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido®, has recently completed a Phase 2 trial in acute lower back pain ;

Scilex Pharmaceuticals and Semnur Pharmaceuticals are wholly-owned subsidiaries of Scilex Holding Company.

Section iconCompany Overview

Headquarters
960 San Antonio Road 100 Palo Alto, California 94303 United States
Phone number
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Founded
2019
Employees
51-200

Section iconFunding & Financials

  • $25M$50M

    Scilex Holding Company's revenue is estimated to be in the range of $25M$50M

Section iconFunding & Financials

  • $25M$50M

    Scilex Holding Company's revenue is estimated to be in the range of $25M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.